Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival of stage IV melanoma in Belgium and the Netherlands.
Suijkerbuijk KPM, Haanen JBAG, Boers-Sonderen MJ, Hospers GAP, Blank CU, van den Berkmortel FWPJ, de Groot JWB, Piersma D, Aarts MJB, van Rijn RS, Vreugdenhil G, Westgeest HM, Kapiteijn E, van der Veldt AAM, van den Eertwegh AJM. Suijkerbuijk KPM, et al. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e118-e119. doi: 10.1111/jdv.17668. Epub 2021 Sep 30. J Eur Acad Dermatol Venereol. 2022. PMID: 34536304 No abstract available.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: suijkerbuijk kpm. Br J Cancer. 2022 May;126(9):1362. doi: 10.1038/s41416-022-01772-z. Br J Cancer. 2022. PMID: 35256756 Free PMC article. No abstract available.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije BJ, van der Veldt AAM, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Among authors: suijkerbuijk kpm. Br J Cancer. 2021 May;124(10):1746. doi: 10.1038/s41416-021-01312-1. Br J Cancer. 2021. PMID: 33723402 Free PMC article. No abstract available.
[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].
van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, Aarts MJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM. van Zeijl MCT, et al. Among authors: suijkerbuijk kpm. Ned Tijdschr Geneeskd. 2018 Jun 15;162:D2420. Ned Tijdschr Geneeskd. 2018. PMID: 30040270 Dutch.
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.
Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. Clin Cancer Res. 2020 May 1;26(9):2268-2274. doi: 10.1158/1078-0432.CCR-19-3322. Epub 2020 Jan 27. Clin Cancer Res. 2020. PMID: 31988197
146 results